IGFBP-3 Methylation-Derived Deficiency Mediates the Resistance to Cisplatin Through the Activation of the IGFIR/Akt Pathway in Non-Small Cell Lung Cancer

Oncogene - United Kingdom
doi 10.1038/onc.2012.146
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

AFAP1‑AS1 Induces Cisplatin Resistance in Non‑small Cell Lung Cancer Through PI3K/AKT Pathway

Oncology Letters
Cancer ResearchOncology
2019English

miR-1269b Drives Cisplatin Resistance of Human Non-Small Cell Lung Cancer via Modulating the PTEN/PI3K/AKT Signaling Pathway

OncoTargets and Therapy
OncologyPharmacology
2020English

miR-181 Regulates Cisplatin-Resistant Non-Small Cell Lung Cancer via Downregulation of Autophagy Through the PTEN/PI3K/AKT Pathway

Oncology Reports
MedicineCancer ResearchOncology
2018English

Gelsolin Promotes Radioresistance in Non–Small Cell Lung Cancer Cells Through Activation of Phosphoinositide 3-Kinase/Akt Signaling

Technology in Cancer Research and Treatment
MedicineCancer ResearchOncology
2016English

LncRNA TATDN1 Contributes to the Cisplatin Resistance of Non-Small Cell Lung Cancer Through TATDN1/miR-451/TRIM66 Axis

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2018English

Epigenetic Activation of FOXF1 Confers Cancer Stem Cell Properties to Cisplatin‑resistant Non‑small Cell Lung Cancer

International Journal of Oncology
Cancer ResearchOncology
2020English

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Ex on 14 Mutant Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

FEN1 Promotes Tumor Progression and Confers Cisplatin Resistance in Non-Small-Cell Lung Cancer

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2017English

LncRNA MALAT1 Regulates the Cell Proliferation and Cisplatin Resistance in Gastric Cancer via PI3K/AKT Pathway

Cancer Management and Research
Oncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy